Outcomes of surgery for stage 4 and 5 retinopathy of prematurity in a developing country

Nazmun N, Situma PW, Sonjoy KD, Malek A


Objective: To assess anatomical and visual outcomes plus complications of surgeries in patients with stage 4 and 5 retinopathy of prematurity in a tertiary eye care centre in Bangladesh.
Methods: Retrospective case series of all patients that underwent surgery for stage 4 and 5 retinopathy of prematurity between January 2015 and January 2018 was carried out. Anatomic outcomes, qualitative visual acuity as well as the complications were assessed.
Results: Thirty three eyes of 25 patients were recruited in the study (12 male and 13 female). Overall 22 (66.7%) of the eyes had complete retinal re-attachment. The percentage for complete re-attachment for stage 4A, 4B, and 5 were 89.5%, 66.7% and 12.5% respectively. Overall 19 eyes (57.6%) had ability to fix and follow objects. This
included 14 eyes (73.7%) in stage 4A, 4 eyes (66.7%) in stage 4B and 2 eyes (25.0%) in stage 5. The commonest complications noted were cataracts (15.2%), vitreous haemorrhage (15.2%) and glaucoma (9.1%).
Conclusion: Anatomical outcomes of surgery for stage 4A retinopathy of prematurity are very encouraging while those of stage 4B and 5 are poorer. Consequently, visual outcomes for stage 4A are also better than those for stage 4B and 5.
Key words: Retinopathy of Prematurity, Outcomes, Surgery, Bangladesh

Full Text:



Asano MK, Papakostas TD, Palma CV, Skondra

D. Visual outcomes of surgery for stage 4 and 5

retinopathy of prematurity. Int Ophthalmol Clin. 2014;


Hartnett ME, Penn JS. Mechanisms and management

of retinopathy of prematurity. N Engl J Med. 2012;


Repka MX, Tung B, Good WV, Capone A, Shapiro

MJ. Outcome of eyes developing retinal detachment

during the early treatment for retinopathy of

prematurity study. Arch Ophthalmol. 2011;


Helen A, Kathleen A, Alice ZC. Efficacy of

intravitreal bevacizumab for stage 3+ retinopathy of

prematurity. N Engl J Med. 2011; 364(7):603–615.

Good WV. Final results of the Early Treatment for

Retinopathy of Prematurity (ETROP) randomized

trial. Trans Am Ophthalmol Soc. 2004; 102:233-250.

Gilmore JH. Surgical management of retinopathy of

prematurity. North. 2008; 29(10):1883–89.

Ramak R, Reza K, Mohammad RE, Fariba G, Mehdi NA, et

al. Surgical management in advanced stages of retinopathy

of prematurity; our experience. J Ophthalmic Vis Res. 2009;


Shah PK. Retinopathy of prematurity: Past, present

and future. World J Clin Pediatr [Internet]. 2016;


Lakhanpal RR, Sun RL, Albini TA, Coffee R, Coats

DK, et al. Visual outcomes after 3-port lens-sparing

vitrectomy in stage 4 retinopathy of prematurity. Arch

Ophthalmol. 2006; 124(5):675–679.

Article S. The International Classification of

Retinopathy of Prematurity Revisited. Arch

Ophthalmol [Internet]. 2005; 123(7):991.

Maguire AM, Treese MT. Lens-sparing vitrectomy

surgery in infants. Arch Ophthalmol. 1992; 110:284–286.

Capone A, Trese MT. Lens-sparing vitreous surgery

for tractional stage 4A retinopathy of prematurity

retinal detachments. Ophthalmology. 2001;


Ertzbischoff LM. A systematic review of anatomical

and visual function outcomes in preterm infants after

scleral buckle and vitrectomy for retinal detachment.

Adv Neonatal Care. 2004; 4:10–19.

Hubbard GB, Cherwick DH, Burian G. Lens-sparing

vitrectomy for stage 4 retinopathy of prematurity.

Ophthalmology. 2004; 111:2274–77.

El Rayes EN, Vinekar A, Capone A. Three-year

anatomic and visual outcomes after vitrectomy for

stage 4B retinopathy of prematurity. Retina. 2008;


Choi J, Kim JH, Kim S-J, Yu YS. Long-term results

of lens-sparing vitrectomy for stages 4B and 5

retinopathy of prematurity. Korean J Ophthalmol.

; 25(5):305–310.

Hartnet ME. Features associated with surgical

outcome in patients with stages 4 and 5 retinopathy

of prematurity. Retina. 2003; 23:322–329.

Xu Y, Zhang Q, Kang X, Zhu Y, Li J, et al. Early

vitreoretinal surgery on vascularly active stage 4

retinopathy of prematurity through the preoperative

intravitreal bevacizumab injection. Acta Ophthalmol.

; 91(4):304–411.


  • There are currently no refbacks.